A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 — Asteroid

Osteogenesis Imperfecta Type III Clinical Trial

Official title:
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)

Status Completed

Clinical Trial Summary

The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.

Clinical Trial Description

This study was previously posted by Mereo Biopharma and was transferred to Ultragenyx in February 2021. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03118570
Study type	Interventional
Source	Ultragenyx Pharmaceutical Inc
Contact
Status	Completed
Phase	Phase 2
Start date	September 11, 2017
Completion date	November 12, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05559801` - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)	Phase 1/Phase 2
	Completed	`NCT01061099` - Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta	Phase 1